$Tonix Pharmaceuticals (TNXP.US)$ Tonix Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for TNX-102 SL, a non-opioid, centrally-acting analgesic for fibromyalgia. The NDA is based on two successful Phase 3 studies showing statistically significant pain reduction. TNX-102 SL has been granted Fast Track designation by the FDA, potentially expediting the review process. Key points: The company expects an FDA decision on approval in 2025, pending acceptance o...
update next week PR
Tonix Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for TNX-102 SL, a non-opioid, centrally-acting analgesic for fibromyalgia. The NDA is based on two successful Phase 3 studies showing statistically significant pain reduction. TNX-102 SL has been granted Fast Track designation by the FDA, potentially expediting the review process.
Key points:
The company expects an FDA decision on approval in 2025, pending acceptance o...
No comment yet